about the author

Max Bayer

Pharma Reporter

mbayer@endpointsnews.com

author articles

Up­dat­ed: Take­da’s Ovid-li­censed drug fails two Phase 3 epilep­sy stud­ies

Last year
R&D

Gilead­'s M&A ap­petite is for deals in the 'mid-sin­gle-dig­it bil­lions,' CEO says

Last year
Deals
Pharma

States join Ok­la­homa ef­fort to con­vince Supreme Court to let them reg­u­late PBMs

Last year
Pharma
Law

Lil­ly ex­ec points to Medicare as more pay full list price for Zep­bound than Moun­jaro

Last year
Pharma

BIO's new CEO takes a pa­tri­ot­ic piv­ot to win back Con­gress, push­ing in­dus­try to re­think Chi­na re­la­tion­ship

Last year
China
In Focus

Paxlovid did not beat place­bo in Stan­ford-led long Covid study

Last year
R&D
Pharma

Oculis touts Phase 2 re­sults in dry eye dis­ease, but most da­ta aren't sta­tis­ti­cal­ly sig­nif­i­cant

Last year
R&D

Ital­ian an­titrust agency in­ves­ti­gates No­var­tis, Bio­gen and oth­ers over Lu­cen­tis biosim­i­lar

Last year
Pharma
FDA+

Ali­gos, Ar­bu­tus and oth­ers tout ear­ly he­pati­tis ef­fi­ca­cy da­ta at #EASL24

Last year
R&D

Ab­b­Vie gets first taste of Ela­here po­ten­tial with new mid-stage win

Last year
R&D
Pharma

Lil­ly ex­ec says de­vel­op­ing new ther­a­pies for lu­pus is 'in scope'

Last year
R&D
Pharma
First page Previous page 12131415
A service from the Financial Times